Tags

Type your tag names separated by a space and hit enter

Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
J Clin Oncol. 2008 Mar 10; 26(8):1260-8.JC

Abstract

PURPOSE

We previously found that the risk of invasive breast cancer varied according to the progestagen component of combined postmenopausal hormone therapy (CHT): progesterone, dydrogesterone, or other progestagens. We conducted the present study to assess how these CHTs were associated with histology- and hormone receptor-defined breast cancer.

PATIENTS AND METHODS

We used data from the French E3N cohort study, with 80,391 postmenopausal women followed for a mean duration of 8.1 years; 2,265 histologically confirmed invasive breast cancers were identified through biennial self-administered questionnaires completed from 1990 to 2002. The relative risks (RRs) were estimated using Cox proportional hazards models.

RESULTS

Compared with postmenopausal hormone therapy (HT) never-use, ever-use of estrogen+progesterone was not significantly associated with the risk of any breast cancer subtype, but increasing duration of estrogen+progesterone was associated with increasing risks of lobular (P = .06) and estrogen receptor-positive/progesterone receptor-negative (ER+/PR-; P = .02). Estrogen+dydrogesterone was associated with a significant increase in risk of lobular carcinoma (RR, 1.7; 95% CI, 1.1 to 2.6). Estrogen+other progestagens was associated with significant increases in risk of ductal and lobular carcinomas (RR, 1.6; 95% CI, 1.3 to 1.8; and 2.0; 95% CI, 1.5 to 2.7, respectively), of ER+/PR+ and ER+/PR- carcinomas (RR, 1.8; 95% CI, 1.5 to 2.1; and 2.6; 95% CI, 1.9 to 3.5, respectively), but not of ER-/PR+ or ER-/PR- carcinomas (RR, 1.0; 95% CI, 0.5 to 2.1; and 1.4; 95% CI, 0.9 to 2.0, respectively).

CONCLUSION

The increase in risk of breast cancer observed with the use of CHTs other than estrogen+progesterone and estrogen+dydrogesterone seems to apply preferentially to ER+ carcinomas, especially those ER+/PR-, and to affect both ductal and lobular carcinomas.

Authors+Show Affiliations

Institut National de la Santé et de la Recherche Médicale, ERI 20, EA 4045, Institut Gustave Roussy, 94805 Villejuif Cedex, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18323549

Citation

Fournier, Agnès, et al. "Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptor-defined Invasive Breast Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 26, no. 8, 2008, pp. 1260-8.
Fournier A, Fabre A, Mesrine S, et al. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol. 2008;26(8):1260-8.
Fournier, A., Fabre, A., Mesrine, S., Boutron-Ruault, M. C., Berrino, F., & Clavel-Chapelon, F. (2008). Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 26(8), 1260-8. https://doi.org/10.1200/JCO.2007.13.4338
Fournier A, et al. Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptor-defined Invasive Breast Cancer. J Clin Oncol. 2008 Mar 10;26(8):1260-8. PubMed PMID: 18323549.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. AU - Fournier,Agnès, AU - Fabre,Alban, AU - Mesrine,Sylvie, AU - Boutron-Ruault,Marie-Christine, AU - Berrino,Franco, AU - Clavel-Chapelon,Françoise, PY - 2008/3/8/pubmed PY - 2008/4/9/medline PY - 2008/3/8/entrez SP - 1260 EP - 8 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J. Clin. Oncol. VL - 26 IS - 8 N2 - PURPOSE: We previously found that the risk of invasive breast cancer varied according to the progestagen component of combined postmenopausal hormone therapy (CHT): progesterone, dydrogesterone, or other progestagens. We conducted the present study to assess how these CHTs were associated with histology- and hormone receptor-defined breast cancer. PATIENTS AND METHODS: We used data from the French E3N cohort study, with 80,391 postmenopausal women followed for a mean duration of 8.1 years; 2,265 histologically confirmed invasive breast cancers were identified through biennial self-administered questionnaires completed from 1990 to 2002. The relative risks (RRs) were estimated using Cox proportional hazards models. RESULTS: Compared with postmenopausal hormone therapy (HT) never-use, ever-use of estrogen+progesterone was not significantly associated with the risk of any breast cancer subtype, but increasing duration of estrogen+progesterone was associated with increasing risks of lobular (P = .06) and estrogen receptor-positive/progesterone receptor-negative (ER+/PR-; P = .02). Estrogen+dydrogesterone was associated with a significant increase in risk of lobular carcinoma (RR, 1.7; 95% CI, 1.1 to 2.6). Estrogen+other progestagens was associated with significant increases in risk of ductal and lobular carcinomas (RR, 1.6; 95% CI, 1.3 to 1.8; and 2.0; 95% CI, 1.5 to 2.7, respectively), of ER+/PR+ and ER+/PR- carcinomas (RR, 1.8; 95% CI, 1.5 to 2.1; and 2.6; 95% CI, 1.9 to 3.5, respectively), but not of ER-/PR+ or ER-/PR- carcinomas (RR, 1.0; 95% CI, 0.5 to 2.1; and 1.4; 95% CI, 0.9 to 2.0, respectively). CONCLUSION: The increase in risk of breast cancer observed with the use of CHTs other than estrogen+progesterone and estrogen+dydrogesterone seems to apply preferentially to ER+ carcinomas, especially those ER+/PR-, and to affect both ductal and lobular carcinomas. SN - 1527-7755 UR - https://www.unboundmedicine.com/medline/citation/18323549/Use_of_different_postmenopausal_hormone_therapies_and_risk_of_histology__and_hormone_receptor_defined_invasive_breast_cancer_ L2 - http://ascopubs.org/doi/full/10.1200/JCO.2007.13.4338?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -